Parkman Healthcare Partners’s Dynavax Technologies DVAX Stock Holding History

Parkman Healthcare Partners’s Portfolio DVAX Stock Details DVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-271,306	Closed	-$2.69M	–	104
2025 Q3	$2.69M	Buy	271,306 +1,175	+0.4%	+$12.2K	0.28%	77
2025 Q2	$2.68M	Buy	270,131 +35,347	+15%	+$372K	0.31%	75
2025 Q1	$3.05M	Buy	234,784 +13,804	+6%	+$183K	0.36%	66
2024 Q4	$2.82M	Buy	220,980 +1,529	+0.7%	+$18.5K	0.38%	63
2024 Q3	$2.44M	Buy	219,451 +2,629	+1%	+$29K	0.31%	69
2024 Q2	$2.43M	Sell	216,822 -49,688	-19%	-$578K	0.33%	72
2024 Q1	$3.31M	Buy	266,510 +12,563	+5%	+$164K	0.41%	69
2023 Q4	$3.55M	Buy	+253,947	New	+$3.53M	0.5%	60
2020 Q4	–	Sell	-200,000	Closed	-$864K	–	87
2020 Q3	$864K	Buy	+200,000	New	+$1.43M	0.23%	74

Other funds holding DVAX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Parkman Healthcare Partners's DVAX Position: Q4 2025 in Review

Parkman Healthcare Partners sold out of Dynavax Technologies (DVAX) in Q4 2025, closing a stake of 271,306 shares — an estimated $2.69M sold.

Parkman Healthcare Partners first reported a position in DVAX in Q3 2020 and held it in 9 quarters. The position peaked at $3.55M in Q4 2023. 266 funds tracked by Wall St. Rank hold DVAX as of Q4 2025.

Parkman Healthcare Partners reported no remaining Dynavax Technologies position as of Q4 2025 after selling out during the quarter.
Parkman Healthcare Partners sold 271,306 Dynavax Technologies shares in Q4 2025, an estimated $2.69M.
Parkman Healthcare Partners first reported a position in Dynavax Technologies in Q3 2020 and held it in 9 quarters.
Parkman Healthcare Partners's Dynavax Technologies position peaked at $3.55M in Q4 2023.
266 funds tracked by Wall St. Rank held Dynavax Technologies as of Q4 2025.

Based on Parkman Healthcare Partners's 13F filing for Q4 2025, filed 17 Feb 2026.